Skip to Main Content

Author Details

Angela G Fleischman
University of California Irvine
1998
53
22
PMIDPaper TitleJournal TitlePublished Year
37265432Podcast 3. Lessons learned: managing financial costs and where you can go for more information.Future Oncol2023
37546389Cigarette smoke stimulates clonal expansion of Jak2<sup>V617F</sup> and Tet2<sup>-/-</sup> cells.Front Oncol2023
37877698Characterizing the microbiome of patients with myeloproliferative neoplasms during a Mediterranean diet intervention.mBio2023
37218534The importance of developing open communication and a professional, long-term relationship between patients with chronic myeloid leukemia and their oncologist.Future Oncol2023
37214789The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase.medRxiv2023
37081809Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.Leuk Lymphoma2023
37361587Myeloproliferative neoplasms - blurring the lines between cancer and chronic inflammatory disorder.Front Oncol2023
37265434Podcast 2. The journey: staying on top of your cancer.Future Oncol2023
37265433The beginning: diagnosis and selecting your doctor.Future Oncol2023
35747843European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera.Hemasphere2022
35475626Fecal Microbial Community Composition in Myeloproliferative Neoplasm Patients Is Associated with an Inflammatory State.Microbiol Spectr2022
35717689Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.Leuk Res2022
35751150Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.Br J Haematol2022
34082375Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.Leuk Res2021
35663100Inflammation in Myeloid Malignancies: From Bench to Bedside.J Immunother Precis Oncol2021
33641864The Microenvironment in Myeloproliferative Neoplasms.Hematol Oncol Clin North Am2021
34231322Drug-like sphingolipid SH-BC-893 opposes ceramide-induced mitochondrial fission and corrects diet-induced obesity.EMBO Mol Med2021
32532990Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots.Nat Commun2020
31908904The SMAC mimetic LCL-161 selectively targets JAK2<sup>V617F</sup> mutant cells.Exp Hematol Oncol2020
31978215N-acetylcysteine inhibits thrombosis in a murine model of myeloproliferative neoplasm.Blood Adv2020
32107559Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.Blood2020
32915978ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.Blood Adv2020
32824092E-Cigarette Exposure Decreases Bone Marrow Hematopoietic Progenitor Cells.Cancers (Basel)2020
32722135Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN.Cancers (Basel)2020
30647074Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.Blood Adv2019
31128484Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.Leuk Res2019
31119475Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.Curr Hematol Malig Rep2019
29614027The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies.Cancers (Basel)2018
29899021Statins enhance efficacy of venetoclax in blood cancers.Sci Transl Med2018
30279971Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.Oncotarget2018
28501635Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.J Theor Biol2017
28060252Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm.J Vis Exp2016
26458983JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model.Exp Hematol2016
26124920Chronic inflammation: is it the driver or is it paving the road for malignant transformation?Genes Cancer2015
26538830Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.Mediators Inflamm2015
25293778BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.Blood2014
23314844Hematopoietic stem cell transplantation for myelofibrosis: where are we now?Curr Opin Hematol2013
24288407Causal role for JAK2 V617F in thrombosis.Blood2013
24081659The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.Blood2013
23656643Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.N Engl J Med2013
23471820TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.Cancer Discov2013
22596167JAK2 V617F down-modulates MPL.Blood2012
22889761Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.Blood2012
22500050ALDH marks leukemia stem cell.Blood2012
21196392The stem cell fitness landscape and pathways of molecular leukemogenesis.Front Biosci (Schol Ed)2011
21860020TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.Blood2011
19797527Same mutation, different allele.Blood2009
16407117Antagonistic effect of CCAAT enhancer-binding protein-alpha and Pax5 in myeloid or lymphoid lineage choice in common lymphoid progenitors.Proc Natl Acad Sci U S A2006
11917122Lineage infidelity in myeloid cells with TCR gene rearrangement: a latent developmental potential of proT cells revealed by ectopic cytokine receptor signaling.Proc Natl Acad Sci U S A2002
11532393Lymphocyte development from hematopoietic stem cells.Curr Opin Genet Dev2001
  • 1 - 50 of 53

Recommended Authors

Valeriya Kuznetsova
University of Alabama at Birmingham
Career Start Year 2018
Number of shared co-authors 0
Virginia Camacho
Boston Children's Hospital, Harvard Medical School
Career Start Year 2014
Number of shared co-authors 0
Sawa Ito
University of Pittsburgh
Career Start Year 2013
Number of shared co-authors 0
Zhijie Wu
and Blood Institute, National Institutes of Health
Career Start Year 2013
Number of shared co-authors 0
Jennifer N Saultz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 18
Dongqing Yan
Inner Mongolia University
Career Start Year 2010
Number of shared co-authors 9
Kim-Hien T Dao
Astex Pharmaceuticals
Career Start Year 2009
Number of shared co-authors 25
Anthony D Pomicter
Huntsman Cancer Institute, University of Utah
Career Start Year 2009
Number of shared co-authors 22
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 4
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 19
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 1
Christopher Y Park
NYU Robert I. Grossman School of Medicine
Career Start Year 2006
Number of shared co-authors 0
Huichun Zhan
Stony Brook School of Medicine
Career Start Year 2005
Number of shared co-authors 0
Fumio Nakahara
Graduate School of Medicine, The University of Tokyo
Career Start Year 2004
Number of shared co-authors 0
Christopher R Cogle
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 19
Robert S Welner
University of Alabama at Birmingham
Career Start Year 2002
Number of shared co-authors 0
Phillip M Clair
Huntsman Cancer Institute, The University of Utah
Career Start Year 2001
Number of shared co-authors 8
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 0
Peter Kurre
Children's Hospital of Philadelphia
Career Start Year 1999
Number of shared co-authors 8
Xingmin Feng
and Blood Institute, National Institutes of Health
Career Start Year 1999
Number of shared co-authors 0
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 8
David M Weinstock
Merck & Co.
Career Start Year 1998
Number of shared co-authors 7
Stephanie Halene
Smilow Cancer Center, Yale University School of Medicine
Career Start Year 1997
Number of shared co-authors 0
Alison R Moliterno
Johns Hopkins Hospital
Career Start Year 1995
Number of shared co-authors 3
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 2
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 5
Paul Brent Ferrell
Vanderbilt University
Career Start Year 1981
Number of shared co-authors 1
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 3
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 1979
Number of shared co-authors 18
John F DiPersio
Washington University School of Medicine
Career Start Year 1978
Number of shared co-authors 7

Collaborators

Brian J Druker
Oregon Health & Science University
Co-authored papers 7
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 6
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 5
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 5
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Samuel B Luty
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Erin Moshier
Co-authored papers 3
Ryan J Mackenzie
Oregon Health & Science University, USA [2] Knight Cancer Institute
Co-authored papers 2
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Bill H Chang
Oregon Health and Science University
Co-authored papers 2
Julia E Maxson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Co-authored papers 2
Grover C Bagby
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 2
Stephen T Oh
Washington University School of Medicine
Co-authored papers 2
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 2
Kavin B Vasudevan
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Dorian LaTocha
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Markus G Manz
Co-authored papers 1
Eduardo Firpo
Fred Hutchinson Cancer Research Center
Co-authored papers 1
Basem S Goueli
Stanford University School of Medicine
Co-authored papers 1
Nicolas Duquesnes
University of Toulouse, CNRS
Co-authored papers 1
Fei Yang
Oregon Health & Science University
Co-authored papers 1
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 1
Jorge Cortes
Georgia Cancer Center
Co-authored papers 1
Arnaud Besson
University of Toulouse, CNRS
Co-authored papers 1
Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers 1
Quy Nguyen
University of California irvine
Co-authored papers 1
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Release 1.2